PF-Atlas › Исследования › mRNA Innovation
Исследования: mRNA Innovation (23)
23 публикаций в теме «mRNA Innovation», проиндексированных PF-Atlas из PubMed и мировых журналов.
- Lung-targeted lipid nanoparticle delivery of a matricellular mRNA promotes fibrotic lung repair. · American journal of respiratory cell and molecular biology · 2026
- CFTR mRNA-Based Gene Therapy for Cystic Fibrosis: A Mutation-Agnostic Strategy to Restore Ion Transport Function. · Current gene therapy · 2026
- LUNAR LNP delivery of CFTR mRNA restores channel function and improves mucociliary clearance in ferret cystic fibrosis airways. · Molecular therapy : the journal of the American Society of Gene Therapy · 2026
- Targeted RNA Therapy Reprograms Fibrotic Macrophages to Reverse Pulmonary Fibrosis. · Theranostics · 2026
- Melatonin-tuned mRNA-loaded lipid nanoparticles enhance NRF2-mediated mesenchymal stem cell therapy for pulmonary fibrosis. · Biomaterials · 2026
- DOTAP-Engineered Lipid Nanoparticles Enable Fibroblast-Targeted CRISPR/Cas9 Delivery for HSP47 Silencing and Pulmonary Fibrosis Therapy. · ACS applied materials & interfaces · 2026
- Achieving the goldilocks zone of lung-targeted mRNA delivery with a charge-steric optimized quantum dot-lipid system for pulmonary fibrosis therapy. · Journal of controlled release : official journal of the Controlled Release Society · 2026
- Unlocking the potential of mRNA nanomedicines for comprehensive fibrosis therapy. · Molecular therapy. Nucleic acids · 2026
- Inhalable lipid nanoparticles for macrophage-specific STING gene editing to ameliorate pulmonary fibrosis. · Molecular therapy : the journal of the American Society of Gene Therapy · 2026
- FAP-Synergistic Organ-Targeted mRNA-LNP for Overcoming Delivery Barriers in Hepatic and Pulmonary Fibrosis. · Journal of the American Chemical Society · 2026
- Optimization of Therapeutic modRNA Delivery to the Lung for Prevention of Pulmonary Fibrosis. · Pharmaceutics · 2026
- Nonviral delivery of chemically modified tRNA rescues nonsense mutations in cystic fibrosis. · Science (New York, N.Y.) · 2026
- 'Tripod-like' lung-targeting lipids for highly efficient and selective LNPs for gene delivery and editing. · Nature biomedical engineering · 2026
- Melittin-loaded solid lipid nanoparticles inhibit pulmonary fibrosis via the NOVA2-TGF-β/Smads signaling pathway. · International immunopharmacology · 2026
- Cas9 Protein Outperforms mRNA in Lipid Nanoparticle-Mediated CFTR Repair. · Nano letters · 2025
- Nanomedicine for lymphangioleiomyomatosis: toward targeted and durable anti-fibrotic therapy. · Annals of medicine and surgery (2012) · 2025
- Lipid nanoparticle-encapsulated Dnai1 mRNA rescues ciliary activity in primary ciliary dyskinesia mouse cell models. · Journal of cell science · 2025
- Non-viral mRNA delivery to the lungs. · Biomaterials science · 2025
- A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects. · Frontiers in immunology · 2025
- Synthesis of ionizable lipopolymers using split-Ugi reaction for pulmonary delivery of various size RNAs and gene editing. · Nature communications · 2025
- Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. · Nature biotechnology · 2025
- A Review of Nanoparticle-Mediated Delivery Systems for RNA-Based Therapeutics. · Recent patents on nanotechnology · 2025
- LPA antagonist-derived LNPs deliver A20 mRNA and promote anti-fibrotic activities. · Nano research · 2024
Медицинская оговорка. Списки исследований приведены только для информации и не являются медицинской рекомендацией.